Glucose targets for preventing diabetic kidney disease and its progression (Q38736800)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28863069 AND SRC:MED&resulttype=core&format=json

22 March 2020

0 references

1 reference

title

Glucose targets for preventing diabetic kidney disease and its progression (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28863069 AND SRC:MED&resulttype=core&format=json

22 March 2020

1 reference

1

Marinella Ruospo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28863069 AND SRC:MED&resulttype=core&format=json

22 March 2020

2

Valeria M Saglimbene

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28863069 AND SRC:MED&resulttype=core&format=json

22 March 2020

3

Suetonia C Palmer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28863069 AND SRC:MED&resulttype=core&format=json

22 March 2020

Salvatore De Cosmo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28863069 AND SRC:MED&resulttype=core&format=json

22 March 2020

Jonathan Craig

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28863069 AND SRC:MED&resulttype=core&format=json

22 March 2020

11

Giovanni Fm Strippoli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28863069 AND SRC:MED&resulttype=core&format=json

22 March 2020

6

Olga Lamacchia

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28863069 AND SRC:MED&resulttype=core&format=json

22 March 2020

7

Mauro Cignarelli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28863069 AND SRC:MED&resulttype=core&format=json

22 March 2020

Mariacristina Vecchio

9

object named as

Mariacristina Vecchio

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28863069 AND SRC:MED&resulttype=core&format=json

22 March 2020

author name string

Antonio Pacilli

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28863069 AND SRC:MED&resulttype=core&format=json

22 March 2020

Paola Fioretto

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28863069 AND SRC:MED&resulttype=core&format=json

22 March 2020

language of work or name

1 reference

8 June 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28863069 AND SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

22 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28863069 AND SRC:MED&resulttype=core&format=json

22 March 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28863069 AND SRC:MED&resulttype=core&format=json

22 March 2020

page(s)

CD010137

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28863069 AND SRC:MED&resulttype=core&format=json

Effects of intensive blood-pressure control in type 2 diabetes mellitus

22 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Albuminuria and cognitive decline in people with diabetes and normal renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Determinants of weight gain in the action to control cardiovascular risk in diabetes trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Clinical implications of the ACCORD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Buffy coat specimens remain viable as a DNA source for highly multiplexed genome-wide genetic tests after long term storage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Association of Urinary Biomarkers of Inflammation, Injury, and Fibrosis with Renal Function Decline: The ACCORD Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Evaluation of an automated method to assist with error detection in the ACCORD central laboratory

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Depression predicts all-cause mortality: epidemiological evaluation from the ACCORD HRQL substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

ADVANCE--Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

ADVANCE: action in diabetes and vascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

The risk of cancer in people with diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Severe hypoglycemia and risks of vascular events and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Lowering blood pressure reduces renal events in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complicat

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Intensive diabetes therapy and ocular surgery in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

T1 mapping of the gadolinium-enhanced myocardium: adjustment for factors affecting interpatient comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Antibodies to GAD65 and peripheral nerve function in the DCCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

The long-term effects of type 1 diabetes treatment and complications on health-related quality of life: a 23-year follow-up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the diabetes control and complications trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Insulin secretion measured by stimulated C-peptide in long-established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Operational and policy considerations of data monitoring in clinical trials: the Diabetes Control and Complications Trial experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Myocardial structure, function, and scar in patients with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Comparison of urinary albumin-creatinine ratio and albumin excretion rate in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Renal outcomes in patients with type 1 diabetes and macroalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Influence of glucose control, lipoproteins, and haemostasis function on brachial endothelial reactivity and carotid intima-media area, stiffness and diameter in Type 1 diabetes mellitus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Mortality and treatment side-effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Nephropathy is delayed by intensified insulin treatment in patients with insulin-dependent diabetes mellitus and retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Intensive insulin therapy in patients with type 2 diabetes: implications of the Veterans affairs (VA CSDM) feasibility trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Observation on renal outcomes in the Veterans Affairs Diabetes Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Blood pressure and pulse pressure effects on renal outcomes in the Veterans Affairs Diabetes Trial (VADT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Association of PAI-1 and fibrinogen with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Association of blood glucose control and pancreatic reserve with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Apolipoprotein-defined and NMR lipoprotein subclasses in the veterans affairs diabetes trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Glucose control and cardiovascular complications: the VA Diabetes Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Control of cardiovascular risk factors in the Veterans Affairs Diabetes Trial in advanced type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Comparison of dilated fundus examinations with seven-field stereo fundus photographs in the Veterans Affairs Diabetes Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Ethnicity, race, and clinically significant macular edema in the Veterans Affairs Diabetes Trial (VADT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Clinical correlates of serum pigment epithelium-derived factor in type 2 diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: the VA Cooperative Study in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

The effect of intensive glucose lowering on lipoprotein particle profiles and inflammatory markers in the Veterans Affairs Diabetes Trial (VADT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Veterans Affairs diabetes trial--corrections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Proliferative diabetic retinopathy in type 2 diabetes is related to coronary artery calcium in the Veterans Affairs Diabetes Trial (VADT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Rates and Determinants of Coronary and Abdominal Aortic Artery Calcium Progression in the Veterans Affairs Diabetes Trial (VADT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Increased plasma basic fibroblast growth factor is associated with coronary heart disease in adult type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Plasma basic fibroblast growth factor is correlated with plasminogen activator inhibitor-1 concentration in adults from the Veterans Affairs Diabetes Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Endothelial cell inhibitory autoantibodies are associated with laser photocoagulation in adults from the Veterans Affairs Diabetes Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Low plasma basic fibroblast growth factor is associated with laser photocoagulation treatment in adult type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Autoantibodies in type 2 diabetes induce stress fiber formation and apoptosis in endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Near normoglycemia for 1 year has no effect on platelet reactivity, factor VIII, and von Willebrand factor in insulin-dependent diabetes mellitus: a controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Effect of blood glucose control on increased glomerular filtration rate and kidney size in insulin-dependent diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Adapting to and managing diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Nephropathy in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Glucose targets for preventing diabetic kidney disease and its progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Prediction of Kidney-Related Outcomes in Patients With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Intensive glucose control improves kidney outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Determining Stability of Stored Samples Retrospectively: The Validation of Glycated Albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: The Microalbuminuria Education and Medication Optimisation (MEMO) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010137.PUB2

Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study

21 January 2018

1 reference

12 December 2020

Decreased heart rate variability in patients with type 1 diabetes mellitus is related to arterial wall stiffness

1 reference

12 December 2020

[Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno-2 study]

1 reference

12 December 2020

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy

1 reference

12 December 2020

The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM)

1 reference

12 December 2020

Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients

1 reference

12 December 2020

Autonomic neuropathy--a complication less pronounced in patients with Type 1 diabetes mellitus who have lower blood glucose levels

1 reference

12 December 2020

Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-R

1 reference

12 December 2020

ADVANCE study: objectives, design and current status

1 reference

12 December 2020

Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group (CSDM)

1 reference

12 December 2020

Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial

1 reference

12 December 2020

Risk factors for progression of microvascular complications in the Stockholm Diabetes Intervention Study (SDIS)

1 reference

12 December 2020

Incidence of end-stage renal disease in patients with type 1 diabetes

1 reference

12 December 2020

Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians

1 reference

12 December 2020

ADVANCE: breaking new ground in type 2 diabetes

1 reference

12 December 2020

1 reference

12 December 2020

Recent progress in the treatment of diabetic nephropathy: Importance of strict glycemic control on the regression of diabetic nephropathy

1 reference

12 December 2020

UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance

1 reference

12 December 2020

Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years

1 reference

12 December 2020

Effects of combination lipid therapy in type 2 diabetes mellitus

1 reference

12 December 2020

Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial

1 reference

12 December 2020

Effects of medical therapies on retinopathy progression in type 2 diabetes

1 reference

12 December 2020

Urinary Catalytic Iron in Patients with Type 2 Diabetes without Microalbuminuria--a Substudy of the ACCORD Trial

1 reference

12 December 2020

Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group

1 reference

12 December 2020

The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers

1 reference

12 December 2020

Metabolic control and complications over 3 years in patients with insulin dependent diabetes (IDDM): the Stockholm Diabetes Intervention Study (SDIS)

1 reference

12 December 2020

Intensified insulin treatment is associated with improvement in skin microcirculation and ischaemic foot ulcer in patients with type 1 diabetes mellitus: a long-term follow-up study

1 reference

12 December 2020

The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group

1 reference

12 December 2020

Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group

1 reference

12 December 2020

The Stockholm Diabetes Intervention Study (SDIS): 18 months' results

1 reference

12 December 2020

Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study

1 reference

12 December 2020

Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin-dependent diabetes mellitus. The Oslo Study

1 reference

12 December 2020

Kidney function during 12 months of strict metabolic control in insulin-dependent diabetic patients with incipient nephropathy

1 reference

12 December 2020

Effect of long-term near-normoglycemia on the progression of diabetic nephropathy

1 reference

12 December 2020

Effect of 6 months of strict metabolic control on eye and kidney function in insulin-dependent diabetics with background retinopathy. Steno study group

1 reference

12 December 2020

Prevention of deterioration of renal and sensory-nerve function by more intensive management of insulin-dependent diabetic patients. A two-year randomised prospective study

1 reference

12 December 2020

Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group

1 reference

12 December 2020

Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus

1 reference

12 December 2020

Changes in conceptions and attitudes during five years of intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study (SDIS)

1 reference

12 December 2020

Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research

1 reference

12 December 2020

The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus

1 reference

12 December 2020

Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group.

1 reference

12 December 2020

Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study

1 reference

12 December 2020

Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10-year follow up

1 reference

12 December 2020

Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

10.1002/14651858.CD010137.PUB2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28863069 AND SRC:MED&resulttype=core&format=json

release_7dgbvzadyff4hjplj4zmkpm7hu

22 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7dgbvzadyff4hjplj4zmkpm7hu

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28863069 AND SRC:MED&resulttype=core&format=json

22 March 2020

PubMed publication ID

28863069

1 reference